Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
QuidelOrtho Corporation QDEL
$86.66
+$0.36 (0.41%)
На 18:00, 12 мая 2023
+29.24%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
5751803720.00000000
-
week52high
108.35
-
week52low
66.88
-
Revenue
3266000000
-
P/E TTM
11
-
Beta
0.29134900
-
EPS
9.78000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 мая 2023 г. в 10:59
Описание компании
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| UBS | Sell | 20 июл 2022 г. | |
| Raymond James | Strong Buy | Strong Buy | 06 мая 2022 г. |
| Raymond James | Strong Buy | Outperform | 22 февр 2022 г. |
| Raymond James | Outperform | Outperform | 06 авг 2021 г. |
| Raymond James | Outperform | Outperform | 28 июн 2021 г. |
| Citigroup | Neutral | 19 сент 2022 г. | |
| UBS | Neutral | Sell | 14 окт 2022 г. |
| JP Morgan | Neutral | Neutral | 03 ноя 2022 г. |
| RBC Capital | Outperform | 07 дек 2022 г. | |
| Citigroup | Buy | Neutral | 12 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| BRYANT DOUGLAS C | D | 2232 | 1115 | 01 февр 2023 г. |
| BRYANT DOUGLAS C | D | 510578 | 553 | 01 февр 2023 г. |
| BRYANT DOUGLAS C | A | 511131 | 1115 | 01 февр 2023 г. |
| Bujarski Robert Joseph | D | 1758 | 879 | 01 февр 2023 г. |
| Bujarski Robert Joseph | D | 31849 | 463 | 01 февр 2023 г. |
| Bujarski Robert Joseph | A | 32312 | 879 | 01 февр 2023 г. |
| Hodges Michelle A. | D | 947 | 473 | 01 февр 2023 г. |
| Hodges Michelle A. | D | 4301 | 162 | 01 февр 2023 г. |
| Hodges Michelle A. | A | 4463 | 473 | 01 февр 2023 г. |
| Kroll Werner | D | 1313 | 1312 | 01 февр 2023 г. |
Новостная лента
QuidelOrtho: 5x Earnings Is Borderline Offensive, Rate Buy At 20x
Seeking Alpha
22 апр 2023 г. в 03:41
QuidelOrtho: 5x Earnings Is Borderline Offensive, Rate Buy At 20x.
QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues
Zacks Investment Research
17 апр 2023 г. в 12:10
QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.
QuidelOrtho (QDEL) Soars 5.0%: Is Further Upside Left in the Stock?
Zacks Investment Research
17 апр 2023 г. в 10:41
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why QuidelOrtho Stock Popped by 5% on Friday
The Motley Fool
15 апр 2023 г. в 06:05
The diagnostics specialist released preliminary first-quarter revenue figures. These easily beat the average analyst estimate.
3 Reasons to Retain QuidelOrtho (QDEL) Stock in Your Portfolio
Zacks Investment Research
23 мар 2023 г. в 13:44
Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.